1stOncology™: Cancer Intelligence Service – Page 135 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

OVM-200 Phase 1 clinical trial accepted for presentation at ASCO

On May 22, 2026 Oxford Vacmedix (OVM), the UK biotech company developing novel immunotherapies to treat cancer reported that the Phase 1b dose expansion part of the Phase 1 trial of OVM-200 will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago at the end of May. The poster presentation will be part of the session on Developmental Therapeutics – Immunotherapy. This follows the publication of Phase 1a, which established dosing, in a Lancet group journal earlier this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

This Phase 1 clinical trial of OVM-200 is a multicentre, open-label, first-in-human evaluation of OVM-200, an immunotherapy developed using Oxford Vacmedix’s Recombinant Overlapping Peptide (ROP) therapeutic platform. 36 patients with advanced NSCLC (non-small cell lung cancer) ovarian cancer, or prostate cancer and with no HLA restrictions, were treated in the trial. The results show:

Excellent Safety Profile (primary endpoint): OVM-200 is very well tolerated with no serious adverse drug reactions or no dose-limiting toxicities. The only adverse effects were Grade 1 injection-site reactions.
Very strong Immunogenicity (secondary endpoint): the immune responses for both antibodies and for T cells were very strong even in an advanced Stage IV patient population.
Therapeutic Dose established (secondary endpoint) based on the immune response, the 2mg dose selected in Phase 1a was chosen for expanded immunisations of up to 11 doses of 2mg in Phase 1b.
Early observations of clinical efficacy with stable disease in NSCLC and PSA responses in prostate cancer following progression to other therapies.
Professor Martin Forster, Chief Investigator at University College Hospital, London, said:

We are very impressed with the results of this Phase 1 trial for OVM-200. In particular, seeing six months stable disease in a Stage IV lung cancer patient is a very promising result, for follow up. We look forward to further development with Phase 2 trials of OVM-200.

William Finch, Chief Executive Officer of Oxford Vacmedix, said:

The completion of this clinical trial of OVM-200 marks an important milestone for the company. We are of course very grateful for the participation of the patients and the dedication of the staff in the clinics in this first trial of OVM-200. We are already in discussions about investment to fund Phase 2 development.

(Press release, Oxford Vacmedix, MAY 22, 2026, View Source;utm_medium=rss&utm_campaign=ovm-200-phase-1-clinical-trial-accepted-for-presentation-at-asco [SID1234666014])

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

On May 22, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, reported preliminary results from a new health economic analysis demonstrating that ANKTIVA (nogapendekin alfa inbakicept-pmln; NAI) plus Bacillus Calmette–Guérin (BCG) achieved a lower cost per sustained complete responder compared to TAR-200 in patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ ± papillary disease (NMIBC CIS). The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention Center in Philadelphia, by Ruchika Talwar, M.D., Medical Director and Assistant Professor Urologic Oncology at Vanderbilt Health.

The authors developed a cost-consequence model comparing ANKTIVA plus BCG, using data from the QUILT-3.032 study, with TAR-200, using data from the SunRISe-1 trial, and evaluated both clinical and economic outcomes in a U.S. Medicare population. A multi-state Markov model incorporating key NMIBC health states and clinical outcomes derived from a matched-adjusted indirect comparison (MAIC) of the two trials was used to assess costs associated with treatment acquisition, administration, healthcare resource utilization, radical cystectomy, and mortality.

Key findings include:

Cost per cystectomy avoided: ANKTIVA plus BCG demonstrated savings of $109,622 at Year 1, $151,438 at Year 2, and $60,393 at Year 3 compared to TAR-200
Cost per cystectomy-free month: Savings of $9,370 at Year 1, $6,144 at Year 2, and $1,520 at Year 3
Cost per complete responder: Savings of $313,775 at Year 1 and $282,013 at Year 2
Cost reductions were primarily driven by lower drug acquisition and administration costs, based on complete response rates derived from an indirect treatment comparison—49.6% for ANKTIVA plus BCG versus 45.9% for TAR-200.

The authors concluded that ANKTIVA plus BCG offers direct cost savings across measurable clinical outcomes for patients with BCG-unresponsive NMIBC CIS compared to TAR-200 in a U.S. Medicare population, with savings persisting across all three years of the analysis.

"This health economic analysis reflects our dual mission of developing breakthrough immunotherapies that meaningfully extend lives, while ensuring these innovations are accessible within the broader healthcare landscape. By analyzing the rigorous economic efficiencies of our treatments, we are better positioned to ensure more patients can receive the most innovative and accessible cancer treatments available today," said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "These results solidify the potential value of ANKTIVA plus BCG in delivering durable responses while reducing costs to the Medicare healthcare system."

"These findings reinforce the importance of aligning clinical innovation with both economic value and patient preferences," said Ruchika Talwar, M.D., Medical Director and Assistant Professor Urologic Oncology at Vanderbilt Health. "In BCG-unresponsive NMIBC, treatment decisions are not solely about response rates; they are about durability, quality of life, and ensuring patients have access to therapies that are both effective and sustainable within the healthcare system."

About BCG-Unresponsive NMIBC CIS

Non-muscle-invasive bladder cancer (NMIBC) represents approximately 75% of all bladder cancer diagnoses in the United States. Patients with carcinoma in situ (CIS) who become unresponsive to BCG therapy face a high risk of recurrence and progression and often have limited bladder-sparing treatment options available.

About ANKTIVA (nogapendekin alfa inbakicept-pmln)

The interleukin-15 (IL-15) cytokine plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones.

IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes.

Please see the complete Indication and Important Safety Information and Prescribing Information for ANKTIVA at Anktiva.com.

(Press release, ImmunityBio, MAY 22, 2026, View Source [SID1234666013])

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation

On May 22, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, reported new survey data highlighting the diverse treatment preferences and decision-making priorities of patients with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

The mixed-methods study, conducted in partnership with Fight Bladder Cancer, a UK-based patient advocacy organization, explored how patients with NMIBC who were currently receiving or had previously received BCG weigh radical cystectomy against bladder-sparing therapies following BCG treatment failure. The study provides a contemporary, patient-centered perspective on the factors influencing treatment decision-making in this setting.

"Treatment decisions for patients with BCG-unresponsive NMIBC are deeply personal and often complex," said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "These findings reinforce the importance of incorporating patient perspectives, quality-of-life considerations, and individual treatment priorities into shared decision-making conversations."

The study used an online questionnaire completed by 86 UK adults living with NMIBC who were currently receiving or had previously been treated with BCG. This survey data was supplemented by one-on-one interviews and focus group discussions. Together, these methods were designed to evaluate treatment experiences, priorities, and trade-off preferences related to bladder-sparing approaches versus radical cystectomy following BCG failure.

The data showed that treatment preferences among UK patients with NMIBC are highly individualized, shaped by past treatment experiences, personal values, and age. Key findings include:

Patients actively receiving BCG were more likely to favor bladder preservation strategies
Patients who had previously undergone radical cystectomy were more likely to support repeating that decision
Older participants demonstrated a lower preference for radical cystectomy
Clinical effectiveness, including impact on recurrence, progression, and life expectancy, was identified as the most important factor influencing treatment decisions
Lifestyle disruption and quality-of-life considerations varied across patients, with male participants expressing greater concern regarding the daily-life impact of radical cystectomy
The authors concluded that UK adults living with NMIBC have widely varying treatment priorities—some placing greater weight on cancer control and life expectancy, while others prioritize quality of life and bladder preservation—with many willing to accept trade-offs, such as more frequent hospital visits, to avoid radical cystectomy. Taken together, the findings underscore that there is no one-size-fits-all approach to treatment decisions in this population, and highlight the importance of individualized, patient-centered care.

(Press release, ImmunityBio, MAY 22, 2026, View Source [SID1234666012])

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

On May 22, 2026 Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, reported the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million.

The financing includes leading U.S. biotechnology institutional investors and mutual funds.

Morgan Stanley acted as the lead book-running manager and BofA Securities acted as book-running manager for the offering. LifeSci Capital, Mizuho and Needham & Company acted as co-lead managers for the offering.

The securities in the registered offering were offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms of the registered offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Morgan Stanley & Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Immix Biopharma, MAY 22, 2026, View Source [SID1234666011])

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

On May 22, 2026 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, reported that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.

Presentation details are as follows:

4:55-5:25pm ET on Wednesday, June 3

The Webcast will be available at the start of the presentation under "Events and Presentations" on the Investors section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.

(Press release, Black Diamond Therapeutics, MAY 22, 2026, View Source [SID1234666010])